Try our mobile app
ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (“Aspen Holdings”) Registration number: 1985/002935/06 Share code: APN ISIN: ZAE000066692 LEI: 635400ZYSN1IRD5QWQ94 and its subsidiaries (collectively “Aspen” or “the Group”) CONTRACT MANUFACTURING AGREEMENT TO INITIATE LOCAL PRODUCTION OF AN ESSENTIAL MEDICINE TO TREAT A CHRONIC DISEASE Aspen is pleased to confirm that it has concluded a fourth contract manufacturing agreement towards its strategic plan to fill its recently expanded sterile manufacturing capacity. One of its wholly-owned South African subsidiaries, Aspen SA Operations (Pty) Ltd, has concluded an agreement with a multinational pharmaceutical group for the technical transfer and commercial manufacture of an essential medicine to treat a chronic disease. The agreement allows for local production of vials in South Africa, to cater to the needs of people with this chronic disease on the African continent and beyond. Aspen has agreed to provide the necessary capacity required for the manufacture of these vials at its existing sterile facility in Gqeberha, South Africa. The Group recently invested R6 billion in these facilities including the high technology equipment and systems that will be used to manufacture state-of-the-art sterile drugs and vaccines, packaged into vials, ampoules, and pre-filled syringes. This collaboration with the multinational pharmaceutical group is consistent with Aspen’s stated objective of playing a meaningful role in enhancing access to affordable medicines in Africa. In related initiatives, Aspen was a leading manufacturer of COVID-19 vaccines for Africa and has secured the rights to manufacture, market and distribute, in Africa, four Aspen-branded routine vaccines critical to the protection of health. Durban 6 September 2023 Sponsor Investec Bank Limited
